Asthma Chronic
27
3
3
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.4%
2 terminated out of 27 trials
86.7%
+0.2% vs benchmark
4%
1 trials in Phase 3/4
38%
5 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (27)
Effects of Inspiratory Muscle Training Added to a Swimming Program in Children With Asthma
Thoracic Spine Rotation Stretching and Scapular Retraction in Asthma Patients
Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma
Breathing Exercises Effect on Lung Functions and Chest Expansion in Asthmatics
Improving the Quality of Care for Asthma Patients at Risk of Exacerbations
Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
Inducible Laryngeal Obstruction in Severe Asthma in Severe Asthma
Remote Patient Monitoring Solution for Chronic Respiratory Disease Management
Pictograms to Facilitate Comprehension of Medical Indications
Feasibility of a Smartphone Application for Asthma Self-management
Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma
Asthma Control in a Dutch Primary Care Population
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
Azithromycin Treatment for the Airway Microbiome in Asthma
Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma
Evaluation of Pharmacist-guided Digital-based Asthma Education for Indonesian Children With Asthma
Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
Feasibility of the BREATHE Asthma Intervention Trial